Home › Compound Library › Descovy (TAF/FTC)

Descovy (TAF/FTC)

Antiretroviralprescriptionoral · inferred

Fixed-dose combination of tenofovir alafenamide 25 mg and emtricitabine 200 mg. Approved for HIV treatment and PrEP in men and transgender women who have sex with men (not studied in receptive vaginal exposure at approval). TAF component yields lower plasma tenofovir with improved renal and bone safety vs Truvada. One pill once daily with food.

Projected serum levels — 1 pill (≈ 225 mg), once daily

Descovy (TAF/FTC)
Descovy (TAF/FTC) modeled serum levels, 1 pill (≈ 225 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 pill (≈ 225 mg) once daily (oral).

Modeled steady state after ~1 days: peak ≈ 85.1 mg, trough ≈ 4.4 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiretroviral
Route modeled
Oral
Model confidence
inferred
Half-life
4.9 h
Common dose
1 pill (≈ 225 mg)
Suggested maximum
1 pill/day
Reference dose range
0.50–1 pill (single dose)
Suggested cadence
once daily

Documented interactions

  • watch
    Biktarvy (BIC/FTC/TAF) + Descovy (TAF/FTC) Stacked effects

    Biktarvy (BIC/FTC/TAF) and Descovy (TAF/FTC) both push the hiv reverse transcriptase nrti in the same direction.

  • watch
    Emtricitabine (FTC / Emtriva) + Descovy (TAF/FTC) Stacked effects

    Descovy (TAF/FTC) and Emtricitabine (FTC / Emtriva) both push the hiv reverse transcriptase nrti in the same direction.

  • watch
    Lamivudine (3TC, Epivir) + Descovy (TAF/FTC) Stacked effects

    Descovy (TAF/FTC) and Lamivudine (3TC, Epivir) both push the hiv reverse transcriptase nrti in the same direction.

Serum checks 4 modeled interaction pairings for descovy (taf/ftc) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER) Mayer KH et al. · Lancet, 2020 DOI

    DISCOVER non-inferiority trial demonstrating F/TAF matched F/TDF for PrEP efficacy with improved renal and bone safety markers.

  2. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment Custodio JM et al. · Antimicrobial Agents and Chemotherapy, 2016 DOI

    PK study supporting TAF use without dose adjustment in moderate-to-severe renal impairment, a key differentiator from TDF.

2 published studies referenced in the app, each with a plain-language summary.